Mumbai, 27th January 2025: The unaudited financial statements for the Q3FY25 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.
Key Consolidated Financial Highlights:
| Particulars | Q3 FY25 | Q3 FY24 |
| Revenues (in Rs Cr) | 185.65 | 140.07 |
| Gross Profit (in Rs Cr) | 123.87 | 85.45 |
| EBITDA (in Rs Cr) | 65.95 | 41.49 |
| EBITDA Margin | 35.50% | 29.60% |
| PAT (in Rs Cr) | 46.78 | 29.78 |
| PAT Margin | 25.2% | 21.30% |
| Quarterly EPS (in Rs) | 5.82 | 3.70 |
Key Highlights for Q3 FY25:
In the third quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs. 185.65 crore compared to Rs. 140.07 crore in Q3 FY24.
Gross Profit for Q3 FY25 stood at Rs. 123.87 crore, with a growth of 45% compared to Rs. 85.45 crore in Q3 FY24.
EBITDA for Q3 FY25 stood at Rs. 65.95 crore, with an EBITDA Margin of 35.50%, as opposed to an EBITDA of Rs. 41.49 crore in Q3 FY24 with an EBITDA margin of 29.60%. This marks an improvement of 591 bps YoY.
The Profit After Tax (PAT) increased by 57% for Q3 FY25 to Rs 46.78 crore, compared to Rs 29.78 crore in Q3 FY24.
The PAT Margin stood at 25.2% in Q3 FY25, compared to 21.30% in Q3 FY24.
ALSO READ: Renowned Author Shiv Khera Launches New Book with Chief Guest Dr. S. Jaishankar
Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, “Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth.”
Disclaimer Statements in this “Document” describing the company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be “forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.
About Supriya Lifescience Ltd.:
Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company’s primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.
Platforms like EasyShiksha.com offer valuable courses that can help you gain the necessary skills.
